Biography
Miriam Schiffer is especially interested in gene and cell therapy after myocardial infarction. Combining both therapies with Nanoparticles opens new options in order to enhance their effectiveness. She completed her apprenticeship as biological technician in the Grünenthal group (2012). Focused on molecular cell biology, she graduated as Master of Science (RWTH Aachen University) in 2016. Since then, she works as research assistant and PhD Student in the department of Cardiac Surgery at the University Hospital Bonn. Under supervision of Prof. Dr. Wilhelm Röll she writes her dissertation with the following title: Lentiviral gene transfer of the ischemic myocardium assisted by magnetic nanoparticles.
Abstract
Besides heart failure, ventricular tachycardia (VT) is one of the most prevalent causes of death following myocardial infarction. Since cardiomyocytes are terminally differentiated cells, they are replaced predominantly by fibroblasts, which maximally proliferate on day 3 to 4 post infarction. Despite cardiac fibroblasts expressing the gap junction protein Connexin 43 (Cx43) on a basal level, propagation of the electrical conduction is reduced massively within the infarction area and VT can originate from re-entry mechanisms. Our goal is to enhance the conduction velocity within the scar by increasing the Cx43 expression in resident fibroblasts through direct intramyocardial lentiviral (LV) gene delivery or by intramyocardial transplantation of Cx43 overexpressing cardiac fibroblasts. Both the LV transduction efficiency and the engraftment of transplanted cells can be enhanced by the application of magnetic Nanoparticles (MNP) and magnetic fields. Besides the higher transduction efficiency, the application of MNP/magnet system enables a localized lentiviral transduction in vitro and in vivo. Our cooperation partners of the “Research Network Europe Japan†provided a PMAO coated magnetic particle labeled with TAMRA fluorochrome. This particle is characterized in vitro by a low toxicity (cell loss of 20 % at 25 pg / cell after 24 hours MNP treatment analyzed in MTT Assay) and high magnetic cell retention (80 % of cells after 24 hours incubation and 100 pg Fe /cell). In addition the used lentiviral (LV) constructs (rrl-CMV-Cx43-IRES-eGFP and rrlCMV-IRES-eGFP) complexed well with this MNP, since gene expression in fibroblasts was similar after overnight incubation without magnet application and following 30 minutes incubation under magnetic attraction. In conclusion, we could show that our target MNP is incorporated into fibroblasts resulting in low toxic effects but high magnetic cell retention. Additionally we were able to demonstrate a successfully complexation of MNP and LV, which allows faster and localized lentiviral cell transduction.
Biography
Esther Carls Has Her Primary Research Interest In Cardiovascular Diseases. She Has Completed Her Bachelor Degree In Life Sciences In 2011 And Her Master Degree In ‘Clinical Molecular Sciences’ In 2012 Focusing On Macrophage Cell Therapy In Atherosclerosis. Following This She Worked At The University Of Edinburgh On Macrophage Cell Therapy In Renal Ischemia. Since 2014 She Has Been Working At The University Hospital Bonn’s Dept. Of Cardiac Surgery On Cell And Gene Therapy In Myocardial Infarction. In 2017 She Started Work On Her Phd Thesis Under The Supervision Of Prof. Dr. Med. Wilhelm Röll.
Abstract
After myocardial infarction, one of the major complications, besides a reduced ejection fraction (EF), is the occurrence of ventricular tachycardia (VT). The loss of cardiomyocytes in the infarction area is structurally compensated by their replacement with fibroblasts during scar formation. The massive loss of Cx43 expression within the infarct zone hampers electrical conduction and favors ventricular tachycardia (VT) by re-entry mechanisms. Therefore we hypothesized that intramyocardial transplantation of Cx43 expressing embryonic cardiac fibroblasts (eCF) following myocardial infarction could reduce post-infarct VT incidence. eCF were harvested on E13.5 and cultured for 7 days and transduced with either a Cx43-IRES-GFP or an IRES-GFP lentivirus (LV) construct in vitro. Subsequently they were loaded with fluorescently labelled, PMAO coated magnetic nanoparticles (MNP) overnight. Mice (female CD1, 10-12 wks.) underwent cryogenic induction of myocardial infarction and 200.000 cells were subsequently injected into the infarction area, either with or without application of a magnetic field. Functional analyses were performed 14 days post op by echocardiography and electrophysiological examination. Injected eCF were retained in the infarction area as shown by GFP expression of fibroblasts in the infarction area as well as the presence of the MNP. In the Cx43 transduced eCF injected mice an increased expression of Cx43 in fibroblasts could be observed. Functional examination revealed significantly increased anterior wall thickening (AWT) and improved arrhythmia resistance in mice injected with Cx43 expressing eCF (+Magnet, 25.0% VT incidence, n=8) compared to mice injected with GFP control virus (+Magnet, 77.7% VT incidence, n=9). However, there were no significant differences in global left ventricular function (fractional shortening) between groups. In conclusion, the transplantation of Cx43 expressing eCF protects against VT after myocardial infarction, but does not improve heart function.